Dyne Therapeutics is weighing options after receiving acquisition interest form bigger pharmaceutical firms, Bloomberg’s Dinesh Nair and Michelle Davis report, citing people with knowledge of the matter. The company has been in talks with adviers about possibilities, including a sale or partnership, the authors note. Shares of Dyne are up over 8% in afternoon trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DYN:
- Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Dyne Therapeutics price target lowered to $27 from $29 at Piper Sandler
- Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Dyne Therapeutics 17.15M share Spot Secondary priced at $17.50
- Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock